Incannex Healthcare Inc. Price/Book Ratio
The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.
- Incannex Healthcare Inc. price/book ratio for the quarter ending 2026-03-31 was 14.36, a 70.69% decline year-over-year.
- Incannex Healthcare Inc. price/book ratio for the quarter ending 2025-12-31 was 1.67, a 99.86% decline year-over-year.
- Incannex Healthcare Inc. price/book ratio for the quarter ending 2025-09-30 was 2.11, a 98.68% decline year-over-year.
- Incannex Healthcare Inc. price/book ratio for the quarter ending 2025-06-30 was 0.47, a 99.62% decline year-over-year.
- Incannex Healthcare Inc. price/book ratio for fiscal 2026 was 14.36.
- Incannex Healthcare Inc. price/book ratio for fiscal 2025 was 1.67, a 99.86% decline from fiscal 2024.
- Incannex Healthcare Inc. price/book ratio for fiscal 2024 was 1,163.99.
- Incannex Healthcare Inc. price/book ratio for fiscal 2023 was 10,941.47.
- Available history
- 2022-06-30 to 2026-03-31
- Data captured
Historical Price/Book Ratio
Annual Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B |